Safety, tolerability, and impact on allergic inflammation of autologous E.coli autovaccine in the treatment of house dust mite asthma - a prospective open clinical trial

Rose, Markus A.; Weigand, Bianca; Schubert, Ralf; Schulze, Johannes; Zielen, Stefan

doi:10.1186/1472-6882-11-45

Cited by 6 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, another utility of autovaccines lies in minimum side effects and importantly also in being tolerated in combination with other medications. Our results and used methods are in line with recent research and recommendations (10,(15)(16)(17) related to adequate administration of immunomodulatory therapy and treatment of recurrent as well as chronic persistent infections. In addition, autovaccination treatment can serve as an alternative option for treating chronic infections (18) while avoiding the emergence and development of antimicrobial resistance.…”

Section: Discussionsupporting

confidence: 88%

Autovaccines – potent tool against chronic vulvovaginal candidiasis

KOREN¹,

ZABORSKA²,

VARGA³

et al. 2023

BLL

View full text Add to dashboard Cite

OBJECTIVE: Our aim was to determine the effect of immunomodulatory therapy in women with chronic and recurrent vulvovaginal candidiasis (RVVC). BACKGROUND: We present recent highlights in the research into vaginal microbiome and consequences of chronic infl ammation such as vulvovaginal candidiasis (VVC). VVC is a widespread vaginal infection primarily caused by Candida albicans. Experience of more than three episodes per year is defi ned as RVVC. METHODS: The strains were isolated from women suffering from the above infections as for the period of 2017 to 2021 and subsequently used in immunomodulatory treatment. The preparation and administration of autovaccination therapy was performed using standard methodology and procedures cited in the manuscript. RESULTS: In total, autovaccines were produced for 73 patients of whom 30 (41 %) were successfully cured by this treatment, 29 (40 %) experienced a partially successful treatment, and in the remaining 14 (19 %), the autovaccination therapy was ineffective. CONCLUSION: We provide current knowledge about alternative (autovaccine) treatment options for female patients with VVC and RVVC diseases and our experience with the outcomes after autovaccine administration that currently has a promising therapeutic potential (Tab. 2, Ref. 18).

show abstract

Section: Discussionsupporting

confidence: 88%

Autovaccines – potent tool against chronic vulvovaginal candidiasis

KOREN¹,

ZABORSKA²,

VARGA³

et al. 2023

BLL

View full text Add to dashboard Cite

show abstract

“…The resident microbiota, such as certain bacteria, helminthes and so forth [33]–[36], has profoundly shaped mammalian immunity, the immunomodulatory potential of which has made them promising candidates for allergic disease therapy. More recently, there is still a gap for a body evidence to elucidate the immunomodulatory function of our main and most common gut microflora- E. coli , although certain epidemiological ones have been operated [19], [20], [37], [38]. Hence in our study, we utilized administration of nonpathogenic E. coli ATCC 25922 before the OVA sensitization and challenged phase, and assessed whether E. coli ATCC 25922 was able to either suppress the induction of allergic airway inflammation or regulate the immune responses.…”

Section: Discussionmentioning

confidence: 99%

Immunomodulatory Effects of Escherichia coli ATCC 25922 on Allergic Airway Inflammation in a Mouse Model

et al. 2013

View full text Add to dashboard Cite

BackgroundHygiene hypothesis demonstrates that the lack of microbial exposure would promote the development of allergic airway disease (AAD). Therefore, the gut microbiota, including Escherichia coli (E. coli), would probably offer a potential strategy for AAD.ObjectiveTo investigate whether E. coli infection is able to suppress the induction of AAD and to elucidate the underlying mechanisms.MethodsNonpathogenic E. coli ATCC 25922 was infected by gavage before AAD phase in three patterns: 108 or 106 CFU in neonates or 108 CFU in adults. Then mice were sensitized and challenged with ovalbumin (OVA) to induce allergic inflammation in both the upper and lower airways. Hallmarks of AAD, in terms of eosinophil infiltration and goblet cell metaplasia in subepithelial mucosa, Th2 skewing of the immune response, and levels of T regulate cells (Tregs), were examined by histological analysis, ELISA, and flow cytometry, respectively.Results E. coli, especially neonatally infected with an optimal dose, attenuated allergic responses, including a decrease in nasal rubbing and sneezing, a reduction in eosinophil inflammation and goblet cell metaplasia in subepithelial mucosa, decreased serum levels of OVA-specific IgE, and reduced Th2 (IL-4) cytokines. In contrast, this effect came with an increase of Th1 (IFN-r and IL-2) cytokines, and an enhancement of IL-10-secreting Tregs in paratracheal lymph nodes (PTLN).Conclusion E. coli suppresses allergic responses in mice, probably via a shift from Th1 to Th2 and/or induction of Tregs. Moreover, this infection is age- and dose-dependent, which may open up novel possibilities for new therapeutic interventions.

show abstract

“…The present study was part of the study “Safety, tolerability, and impact on allergic inflammation of autologous E.coli autovaccine in the treatment of house dust mite asthma - a prospective open clinical trial” [ 17 ]. Participants were screened to have a positive skin-prick test and a positive bronchial challenge against household dust mites, as well as increases in eNO and in sputum cells and cytokines.…”

Section: Methodsmentioning

confidence: 99%

Airway responses and inflammation in subjects with asthma after four days of repeated high-single-dose allergen challenge

Schulze¹,

Voss²,

Zissler³

et al. 2012

Respir Res

Self Cite

View full text Add to dashboard Cite

BackgroundBoth standard and low-dose allergen provocations are an established tool in asthma research to improve our understanding of the pathophysiological mechanism of allergic asthma. However, clinical symptoms are less likely to be induced. Therefore, we designed a protocol for repetitive high-dose bronchial allergen challenges to generate clinical symptoms and airway inflammation.MethodsA total of 27 patients aged 18 to 40 years with positive skin-prick tests and mild asthma underwent repetitive high-dose allergen challenges with household dust mites for four consecutive days. Pulmonary function and exhaled NO were measured at every visit. Induced sputum was analysed before and after the allergen challenges for cell counts, ECP, IL-5, INF-γ, IL-8, and the transcription factor Foxp3.ResultsWe found a significant decrease in pulmonary function, an increased use of salbutamol and the development of a late asthmatic response and bronchial hyperresponsiveness, as well as a significant induction of eNO, eosinophils, and Th-2 cytokines. Repeated provocation was feasible in the majority of patients. Two subjects had severe adverse events requiring prednisolone to cope with nocturnal asthma symptoms.ConclusionsRepeated high-dose bronchial allergen challenges resulted in severe asthma symptoms and marked Th-2-mediated allergic airway inflammation. The high-dose challenge model is suitable only in an attenuated form in diseased volunteers for proof-of-concept studies and in clinical settings to reduce the risk of severe asthma exacerbations.Trial registrationClinicalTrials.govNCT00677209

show abstract

Safety, tolerability, and impact on allergic inflammation of autologous E.coli autovaccine in the treatment of house dust mite asthma - a prospective open clinical trial

Cited by 6 publications

References 9 publications

Autovaccines – potent tool against chronic vulvovaginal candidiasis

Autovaccines – potent tool against chronic vulvovaginal candidiasis

Immunomodulatory Effects of Escherichia coli ATCC 25922 on Allergic Airway Inflammation in a Mouse Model

Airway responses and inflammation in subjects with asthma after four days of repeated high-single-dose allergen challenge

Contact Info

Product

Resources

About